Mycoplasma Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, mycoplasma testing market size in 2026 is estimated at USD 1.26 billion, growing from 2025 value of USD 1.13 billion with 2031 projections showing USD 2.12 billion, growing at 11.10% CAGR over 2026-2031.

This report Segments the Industry Into by Product (Instruments, Kits and Reagents, Services), Technology (Conventional PCR, QPCR, and More), Application (Cell-Line Quality Control, and More), End User (Biopharma and Biotechnology Companies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Mycoplasma Testing Market Trends and Insights

Expansion of Biopharma and Cell & Gene Therapy Manufacturing Facilities

Capacity ramp-ups in autologous and allogeneic therapy plants have multiplied sample volumes that require 100% batch testing. Contamination prevalence in cell cultures ranges between 15% and 35%, and FDA guidance now mandates mycoplasma testing after pooling and prior to washing, increasing sampling frequency. Continuous perfusion bioreactors raise real-time monitoring needs, pushing demand for automated analyzers that handle higher throughputs with minimal human intervention. Facility roll-outs in emerging markets must complete qualification studies, creating greenfield demand for third-party test services. Together, these trends add 2.8 percentage points to the forecast CAGR.

Regulatory Mandates Require Mycoplasma Release Testing for Biologics

The FDA's laboratory developed tests rule and EMA guidance for advanced therapy medicinal Products require validated assays from a master cell bank to a finished drug. The European Medicines Agency's guidelines for Advanced Therapy Medicinal Products mandate comprehensive mycoplasma testing throughout the manufacturing process, from master cell banks to final product release. These regulatory changes create non-discretionary demand for testing services, as manufacturers cannot release products without demonstrating mycoplasma absence through validated methods. Compliance spending accelerates through 2027 as phased LDT oversight takes effect.The phased implementation of new LDT regulations over four years creates predictable demand growth as laboratories upgrade their testing capabilities to maintain compliance.

High Capital Expenditure for Implementing Automated Detection Systems

Entry-level automated analyzers cost USD 100,000-500,000, with annual service contracts topping USD 50,000. Smaller CTLs and academic labs struggle to justify such outlays, prolonging reliance on manual culture methods. FDA LDT compliance adds validation costs and strains capital budgets, curbing near-term uptake. Smaller contract testing laboratories face particular challenges in justifying automation investments given their limited sample volumes and diverse testing requirements. The complexity of validating automated systems for regulatory compliance adds significant time and cost burdens, with validation studies typically requiring 6-12 months and specialized expertise.

Other drivers and restraints analyzed in the detailed report include:

1. Increasing Incidents of Cell-Culture Contamination
2. Rising Demand for Rapid, High-Sensitivity PCR-Based Assays
3. False-Positive/-Negative Retest Delays

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Kits and reagents maintained a 45.72% share in 2025, underlining their consumable nature within the Mycoplasma testing market. The Services segment is set to expand at 14.15% CAGR as biomanufacturers delegate method validation and routine screening to accredited laboratories. High regulatory hurdles and evolving assay formats encourage companies to buy expert capacity instead of building it. Eurofins' network of 45+ global sites illustrates how scale produces cost-efficiencies that individual firms cannot replicate.

Automation-ready instruments show steady but slower growth because purchasers often tie them to long-term reagent contracts. The BIOFIRE platform and Rapid Micro Biosystems' vial-reader appeal by blending speed with pharmacopeial compliance. As services grow, kit vendors align with third-party labs under reagent-rental models that lock in supply revenues. This synergy consolidates buyer-supplier dependencies and drives volume in both categories.

qPCR holds 63.85% of the 2025 Mycoplasma testing market share thanks to entrenched protocols and broad instrument availability. Digital PCR, with a 15.75% growth rate, mitigates standard-curve errors and detects rare events vital for gene-therapy lots. Sensitivity gains resonate with regulatory auditors seeking robust quantification. Conventional PCR remains a budget choice for legacy facilities, while ELISA and DNA staining stay relevant in niche academic applications. Next-generation sequencing promises multiplex pathogen screens but awaits regulatory consensus.

Regulatory bodies now accept nucleic-acid methods equivalent to culture for release testing, catalysing digital PCR uptake. Instrument makers invest in microfluidic chip formats that slice reaction mixes into thousands of partitions, lowering detection thresholds. AI augmentation further lessens operator skill barriers, unlocking broader lab adoption.

Complete Report Scope:

• By Product & Service
  • Instruments
    • Real-time PCR Systems
    • Rapid Microfluidic Analyzers
    • Automated Detection Platforms
    • Other Instruments
  • Kits & Reagents
    • PCR Assay Kits
    • ELISA Kits
    • Enzymatic Assay Kits
    • Fluorescent-Staining Reagents
    • Others
  • Services
• By Technology
  • Conventional PCR
  • qPCR
  • Digital PCR
  • ELISA
  • Enzymatic Methods
  • DNA Staining
  • Next-Generation Sequencing
  • Other NAATs
• By Application
  • Cell-Line Quality Control
  • Bioproduction Batch-Release Testing
  • Raw-Material & Media Testing
  • Gene & Cell Therapy Manufacturing
  • Vaccine & Virus Testing
  • Other Applications
• By End User
  • Biopharma & Biotechnology Companies
  • Contract Manufacturing Organizations (CMOs)
  • Academic & Research Institutes
  • Cell Banks & Repositories
  • Diagnostic & Reference Laboratories
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led with 40.25% of 2025 revenue as FDA oversight, mature bioprocessing infrastructure, and early technology adoption underpin stable demand. The region's biocluster density and capital availability encourage rapid replacement of culture methods with automated PCR systems. Service providers leverage proximity to innovators, enabling just-in-time sample logistics and compliance audits.

Europe follows with a cohesive regulatory framework from the EMA and harmonised pharmacopoeias that facilitate multi-country lot release. The Mycoplasma testing market size tied to EU gene-therapy trials rises as Germany, Spain, and the United Kingdom host GMP facilities. Vendors cater to multi-language documentation and serialization demands, spurring informatics-enabled assay platforms.

Asia-Pacific represents the fastest-growing arena, expanding at 18.10% CAGR. China's cell-therapy sector benefits from government priority listings, while India's production-linked incentive schemes attract vaccine exporters. Singapore's decentralized QC labs shorten turnaround times for regional biologics plants. Fragmented regulations necessitate local validation, favouring global companies that co-locate service hubs.

South America and the Middle East & Africa trail in absolute revenue but offer untapped upside as domestic vaccine programs and biosimilar plants proliferate. Logistics hurdles and limited cold-chain infrastructure slow penetration of rapid PCR devices, yet public-health investments could unlock future orders once training and service networks mature.

1. Thermo Fisher Scientific
2. Charles River Laboratories Intl. Inc.
3. Merck
4. Lonza Group Ltd.
5. Eurofins
6. Sartorius
7. Agilent Technologies
8. ATCC
9. PromoCell
10. Minerva Biolabs GmbH
11. bioMerieux
12. Bionique Testing Laboratories
13. WuXi App Tec
14. SGS
15. Danaher
16. Rapid Micro Biosystems
17. MicroBioLogics Inc.
18. InvivoGen
19. Mycoplasma Experience Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support